drugset / Trial / NCT03081481
Intraprostatic PRX302 Injection to Treat Localised Prostate Cancer
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to determine a safe, effective, and tolerable dose of PRX302 for the treatment of low to intermediate risk prostate cancer.
Timeline
- Start
- 2017-06-07
- Primary completion
- 2018-11-28
- Completion
- 2019-04-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | TOPSALYSIN | Unknown | — | Other |